Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Why You Shouldn’t Drink the PepsiCo Punch

By Will Ashworth, InvestorPlace Contributor
PEP may have a squeaky clean exterior, but here are some reasons you may want to think twice about owning the stock.

Kroger Investors Should Switch Grocers

By Will Ashworth, InvestorPlace Contributor
Free cash flow and valuation reveal this other supermarket as a solid substitute for Kroger stockholders.

6 Top Stocks to Sell in September

By Sam Collins, InvestorPlace Chief Technical Analyst
The market is in a precarious technical state, and poor performers should be unloaded on any rally. Show these six the exit first.

Don’t Wait Through Kraft’s Drawn-Out Split

By Will Ashworth, InvestorPlace Contributor
Even if Kraft's proposed spinoff works, it could be years before it's reflected in a significant stock price jump.

It May Be Time to Lose Discover Financial Shares

By Will Ashworth, InvestorPlace Contributor
After its spinoff by Morgan Stanley, Discover Financial has outperformed its parent, but MS stock is better poised to grow.

Procter & Gamble Hard to Appreciate

By Will Ashworth, InvestorPlace Contributor
Procter & Gamble's dividend income is considerable, but equity investors should beware this company's capital appreciation.

What Ails UnitedHealth

By Will Ashworth, InvestorPlace Contributor
Share repurchases, meager dividends, low margins and pending regulations cloud prospects for UnitedHealth Group's stock.

Sell While CBS’ Star Is Still Bright

By Will Ashworth, InvestorPlace Contributor
The media outlet's numbers aren't all pristine, and the potential leadership fallout should Redstone suddenly pass away is a legitimate concern.

Chesapeake Energy: Natural Gas or Hot Air?

By Will Ashworth, InvestorPlace Contributor
Chesapeake Energy's stock is up 54% in the past year. The question is whether CHK can keep it up. See why our verdict is "no."

Starbucks Is Selling Green Mountain’s K-Cups — You Should, Too

By Will Ashworth, InvestorPlace Contributor
GMCR has a pile of chips on the table and a brewing battle with Nestle on its hands.

Kimberly-Clark: Investors Should Go Out On Top

By Will Ashworth, InvestorPlace Contributor
KMB has performed admirably and it's a solid play for income investors, but if you're looking for capital appreciation, look elsewhere.

9 Big-Name Consumer Stocks to Sell

By Louis Navellier, Editor, Growth Investor
Each of these consumer giants is failing or coming close, meaning it's time to wave bye-bye to these nine stocks.

Pack Up, Move Out of Equity Residential

By Will Ashworth, InvestorPlace Contributor
EQR's increase in apartment rents hasn't fueled a rise in its funds from operations, and investors aren't getting their money's worth in returns.

Casino Stock Melco Crown Is About to Crap Out

By Will Ashworth, InvestorPlace Contributor
Melco Crown NASDAQ:MPEL stock is off -21% in 30 days despite strong earnings, thanks to mainland China scrutiny and global economic slowdown.

5 Stocks Buffett Wouldn’t Touch No Matter What Price

By Jamie Dlugosch, InvestorPlace Writer
These companies, all with heavily battered share prices, throw up Buffett's traditional warning flags.

Amgen: The Don’t-Bother Biotech

By Lawrence Meyers, InvestorPlace Contributor
Despite being a cash cow, Amgen is stuck in a middle ground where it isn't growing, nor is it producing a tempting dividend.

Sell Payless, Stride Rite Parent PSS as it Closes 475 Retail Stores

By Jeff Reeves
Payless ShoeSource parent Collective Brands (PSS) is closing 475 stores after it just announced a brutal earnings report. Sell this stock now.

Expedia Shares – 3 Pros, 3 Cons

By Tom Taulli, InvestorPlace Contributor
Expedia is innovative and diligent, but general economic conditions and emerging competition weigh on the stock’s prospects. See our buy-or-sell verdict.

No Reason to Hold Merck

By Lawrence Meyers, InvestorPlace Contributor
As long as this big-name pharmaceutical's growth continues to stagnate, its stock price isn't going anywhere, either.
Load More Articles